|
US8236A
(en)
|
|
1851-07-22 |
|
Hanging cakriage-body |
|
US319A
(en)
|
|
1837-07-31 |
|
Improvement in machines for breaking and dressing hemp and flax |
|
US4434150A
(en)
|
1981-10-19 |
1984-02-28 |
Ortho Diagnostic Systems, Inc. |
Immunological reagents employing polymeric backbone possessing reactive functional groups
|
|
US4486414A
(en)
|
1983-03-21 |
1984-12-04 |
Arizona Board Of Reagents |
Dolastatins A and B cell growth inhibitory substances
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US4880935A
(en)
|
1986-07-11 |
1989-11-14 |
Icrf (Patents) Limited |
Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
|
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
US4936824A
(en)
|
1987-05-15 |
1990-06-26 |
The Boc Group, Inc. |
Infant incubator with air curtain
|
|
US4880078A
(en)
|
1987-06-29 |
1989-11-14 |
Honda Giken Kogyo Kabushiki Kaisha |
Exhaust muffler
|
|
US4816444A
(en)
|
1987-07-10 |
1989-03-28 |
Arizona Board Of Regents, Arizona State University |
Cell growth inhibitory substance
|
|
IL106992A
(en)
|
1988-02-11 |
1994-06-24 |
Bristol Myers Squibb Co |
Acylhydrazone derivatives of anthracycline and methods for their preparation
|
|
US5076973A
(en)
|
1988-10-24 |
1991-12-31 |
Arizona Board Of Regents |
Synthesis of dolastatin 3
|
|
EP0368684B2
(en)
|
1988-11-11 |
2004-09-29 |
Medical Research Council |
Cloning immunoglobulin variable domain sequences.
|
|
US4978744A
(en)
|
1989-01-27 |
1990-12-18 |
Arizona Board Of Regents |
Synthesis of dolastatin 10
|
|
JPH0684824B2
(ja)
|
1989-05-15 |
1994-10-26 |
清水建設株式会社 |
香り供給方法および香り供給装置
|
|
US4879278A
(en)
|
1989-05-16 |
1989-11-07 |
Arizona Board Of Regents |
Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
|
|
US4986988A
(en)
|
1989-05-18 |
1991-01-22 |
Arizona Board Of Regents |
Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5138036A
(en)
|
1989-11-13 |
1992-08-11 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
|
|
US5124471A
(en)
|
1990-03-26 |
1992-06-23 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Bifunctional dtpa-type ligand
|
|
WO1992019244A2
(en)
|
1991-05-01 |
1992-11-12 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
A method for treating infectious respiratory diseases
|
|
US6287792B1
(en)
|
1991-06-17 |
2001-09-11 |
The Regents Of The University Of California |
Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
|
US6034065A
(en)
|
1992-12-03 |
2000-03-07 |
Arizona Board Of Regents |
Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5410024A
(en)
|
1993-01-21 |
1995-04-25 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide amides
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
WO1994016729A1
(en)
|
1993-01-28 |
1994-08-04 |
Neorx Corporation |
Targeted nitric oxide pathway or nitric oxide synthase modulation
|
|
US5934272A
(en)
|
1993-01-29 |
1999-08-10 |
Aradigm Corporation |
Device and method of creating aerosolized mist of respiratory drug
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
WO1995015770A1
(en)
|
1993-12-09 |
1995-06-15 |
Neorx Corporation |
Pretargeting methods and compounds
|
|
US5530097A
(en)
|
1994-08-01 |
1996-06-25 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory peptide amides
|
|
US5521284A
(en)
|
1994-08-01 |
1996-05-28 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide amides and esters
|
|
US5504191A
(en)
|
1994-08-01 |
1996-04-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide methyl esters
|
|
US5554725A
(en)
|
1994-09-14 |
1996-09-10 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Synthesis of dolastatin 15
|
|
US5599902A
(en)
|
1994-11-10 |
1997-02-04 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Cancer inhibitory peptides
|
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
|
US6019968A
(en)
|
1995-04-14 |
2000-02-01 |
Inhale Therapeutic Systems, Inc. |
Dispersible antibody compositions and methods for their preparation and use
|
|
ATE234635T1
(de)
|
1995-12-22 |
2003-04-15 |
Bristol Myers Squibb Co |
Verzweigte hydrazongruppen enthaltende kuppler
|
|
IT1282692B1
(it)
|
1996-02-27 |
1998-03-31 |
San Raffaele Centro Fond |
Citochine modificate per l'uso in terapia
|
|
DK0885002T3
(da)
|
1996-03-04 |
2011-08-22 |
Penn State Res Found |
Materialer og fremgangsmåder til forøgelse af cellulær internalisering
|
|
US5874064A
(en)
|
1996-05-24 |
1999-02-23 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
|
US5985309A
(en)
|
1996-05-24 |
1999-11-16 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
|
US5855913A
(en)
|
1997-01-16 |
1999-01-05 |
Massachusetts Instite Of Technology |
Particles incorporating surfactants for pulmonary drug delivery
|
|
DE69732306T2
(de)
|
1997-01-16 |
2006-01-12 |
Massachusetts Institute Of Technology, Cambridge |
Zubereitung von partikelhaltigen arzneimitteln zur inhalation
|
|
JP2001511811A
(ja)
|
1997-02-13 |
2001-08-14 |
ボーン ケア インターナショナル インコーポレイテッド |
ビタミンｄ化合物の標的治療放出
|
|
DE69832158T2
(de)
|
1997-02-25 |
2006-08-10 |
Arizona Board Of Regents, Tempe |
Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18
|
|
JPH11154024A
(ja)
|
1997-09-16 |
1999-06-08 |
Sumitomo Electric Ind Ltd |
負荷液圧の制御方法
|
|
AU9692498A
(en)
|
1997-10-10 |
1999-05-03 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Complex of biotinylated viral vector and ligand for targeted gene delivery
|
|
US6280955B1
(en)
|
1997-12-16 |
2001-08-28 |
Tularik Inc. |
Interleukin-1 receptor accessory proteins, nucleic acids and methods
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
CA2336139C
(en)
|
1998-06-24 |
2008-10-14 |
Advanced Inhalation Research, Inc. |
Large porous particles emitted from an inhaler
|
|
EP1176195B1
(en)
|
1999-04-09 |
2013-05-22 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
AU6186900A
(en)
|
1999-07-31 |
2001-02-19 |
Kyu Jin Park |
Study method and apparatus using digital audio and caption data
|
|
US6323315B1
(en)
|
1999-09-10 |
2001-11-27 |
Basf Aktiengesellschaft |
Dolastatin peptides
|
|
AU2001271273A1
(en)
|
2000-05-24 |
2001-12-03 |
Ludwig Institute For Cancer Research |
Multicomponent conjugates which bind to target molecules and stimulate cell lysis
|
|
EP2322644A1
(en)
|
2000-06-28 |
2011-05-18 |
GlycoFi, Inc. |
Methods for producing modified glycoproteins
|
|
US7449308B2
(en)
|
2000-06-28 |
2008-11-11 |
Glycofi, Inc. |
Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
|
|
AU2013203432A1
(en)
|
2000-06-29 |
2013-05-02 |
Abbvie Inc. |
Dual specificity antibodies and methods of making and using
|
|
US20030026806A1
(en)
|
2000-10-27 |
2003-02-06 |
Amgen Inc. |
Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
|
|
US20030083263A1
(en)
|
2001-04-30 |
2003-05-01 |
Svetlana Doronina |
Pentapeptide compounds and uses related thereto
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
US20030138803A1
(en)
|
2001-07-27 |
2003-07-24 |
Brooksbank Robert Alan |
Identification and use of molecules implicated in pain
|
|
US20030049255A1
(en)
|
2001-08-07 |
2003-03-13 |
Sims John E. |
Interleukin-1 receptors in the treatment of diseases
|
|
JP2005503789A
(ja)
|
2001-08-17 |
2005-02-10 |
イーライ・リリー・アンド・カンパニー |
抗Ａβ抗体
|
|
HUP0600342A3
(en)
|
2001-10-25 |
2011-03-28 |
Genentech Inc |
Glycoprotein compositions
|
|
WO2003093793A2
(en)
|
2002-05-01 |
2003-11-13 |
Trellis Bioscience, Inc. |
Binary or polynary targeting and uses thereof
|
|
SI1545613T1
(sl)
|
2002-07-31 |
2011-11-30 |
Seattle Genetics Inc |
Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
|
|
JP2006500364A
(ja)
|
2002-08-16 |
2006-01-05 |
イムノージェン インコーポレーテッド |
高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用
|
|
CA2824167C
(en)
|
2002-09-06 |
2018-09-25 |
Amgen Inc. |
Therapeutic human anti-il-1r1 monoclonal antibody
|
|
US7388079B2
(en)
|
2002-11-27 |
2008-06-17 |
The Regents Of The University Of California |
Delivery of pharmaceutical agents via the human insulin receptor
|
|
AR045614A1
(es)
|
2003-09-10 |
2005-11-02 |
Hoffmann La Roche |
Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
|
|
US20050129685A1
(en)
|
2003-09-18 |
2005-06-16 |
Jingtai Cao |
Use of IL-1 blockers to prevent corneal inflammation and neovascularization
|
|
US7498298B2
(en)
|
2003-11-06 |
2009-03-03 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation to ligands
|
|
WO2005081898A2
(en)
|
2004-02-20 |
2005-09-09 |
The Trustees Of The University Of Pennsylvania |
Binding peptidomimetics and uses of the same
|
|
US20050226882A1
(en)
|
2004-04-08 |
2005-10-13 |
Awdalla Essam T |
Method and multicomponent conjugates for treating cancer
|
|
EP1737969B2
(en)
|
2004-04-15 |
2018-09-12 |
GlycoFi, Inc. |
Production of galactosylated glycoproteins in lower eukaryotes
|
|
JP5064212B2
(ja)
|
2004-05-05 |
2012-10-31 |
ヴァロリザーシヨン−ルシェルシュ，ソシエテ・アン・コマンディット |
インターロイキン−１受容体アンタゴニスト、組成物、及び治療方法
|
|
US8618054B2
(en)
|
2004-05-05 |
2013-12-31 |
Valorisation-Rechereche Société en Commandite |
Interleukin-1 receptor antagonists, compositions, and methods of treatment
|
|
RU2402548C2
(ru)
|
2004-05-19 |
2010-10-27 |
Медарекс, Инк. |
Химические линкеры и их конъюгаты
|
|
KR20120064120A
(ko)
|
2004-06-01 |
2012-06-18 |
제넨테크, 인크. |
항체 약물 접합체 및 방법
|
|
GB0419124D0
(en)
|
2004-08-27 |
2004-09-29 |
Proteome Sciences Plc |
Methods and compositions relating to Alzheimer's disease
|
|
EP1695717A1
(en)
|
2005-02-23 |
2006-08-30 |
Ludwig-Maximilians-Universität |
Transport of nano-and macromolecular structures into cytoplasm and nucleus of cells
|
|
AU2014203217B2
(en)
|
2005-08-19 |
2017-03-30 |
Abbvie Inc. |
Dual variable domain immunoglobin and uses thereof
|
|
AU2006304778B2
(en)
|
2005-10-21 |
2011-04-28 |
Amgen Inc. |
Methods of decreasing vascular calcification using IL-1 inhibitors
|
|
JP2009527535A
(ja)
|
2006-02-22 |
2009-07-30 |
ユニバーシティ オブ チューリッヒ |
自己免疫疾患又は脱髄疾患を処置するための可溶性受容体及び方法
|
|
WO2007150020A1
(en)
|
2006-06-23 |
2007-12-27 |
Simon Paul M |
Targeted immune conjugates
|
|
US7560530B1
(en)
|
2006-07-20 |
2009-07-14 |
Schering Corporation |
IL-33 receptor
|
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
|
US7833527B2
(en)
*
|
2006-10-02 |
2010-11-16 |
Amgen Inc. |
Methods of treating psoriasis using IL-17 Receptor A antibodies
|
|
US7632490B2
(en)
|
2006-10-20 |
2009-12-15 |
Regeneron Pharmaceuticals, Inc. |
Use of IL-1 antagonists to treat gout
|
|
US7598028B2
(en)
|
2006-11-28 |
2009-10-06 |
The Regents Of The University Of Michigan |
Compositions and methods for detecting and treating prostate disorders
|
|
WO2008086064A2
(en)
|
2007-01-03 |
2008-07-17 |
The Regents Of The University Of California |
An apparatus and method for in vivo intracellular transfection of gene, sirna, shrna vectors, and other biomedical diagnostic and therapeutic drugs and molecules for the treatment of arthritis and other orthopedic diseaseas in large animals and humans
|
|
KR20090114430A
(ko)
|
2007-02-02 |
2009-11-03 |
베일러 리서치 인스티튜트 |
항원-제시 세포 상에서 발현된 ｄｃｉｒ에 대한 항원 표적화에 기초한 백신
|
|
TWI422594B
(zh)
|
2007-02-02 |
2014-01-11 |
Baylor Res Inst |
經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
|
|
SG178789A1
(en)
|
2007-02-16 |
2012-03-29 |
Merrimack Pharmaceuticals Inc |
Antibodies against erbb3 and uses thereof
|
|
US20080254047A1
(en)
|
2007-02-23 |
2008-10-16 |
Baylor Research Institute |
Activation of Human Antigen-Presenting Cells Through CLEC-6
|
|
NZ579257A
(en)
|
2007-02-23 |
2011-05-27 |
Baylor Res Inst |
Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1)
|
|
EP2208737B1
(en)
|
2007-05-03 |
2017-07-05 |
Lysomab GmbH |
Complement factor H-derived short consensus repeat-antibody constructs
|
|
US10105441B2
(en)
|
2007-08-16 |
2018-10-23 |
The Schepens Eye Research Institute, Inc. |
Method for inhibiting or reducing dry eye disease by IL-1Ra
|
|
JP2011515497A
(ja)
|
2008-03-26 |
2011-05-19 |
セレラント セラピューティクス インコーポレイテッド |
骨髄性血液学的増殖性疾患と関連する免疫グロブリンおよび／またはＴｏｌｌ様受容体タンパク質ならびにその使用
|
|
CN101348526B
(zh)
|
2008-08-29 |
2011-08-17 |
浙江大学 |
一种抗白细胞介素-8抗体
|
|
US8298533B2
(en)
|
2008-11-07 |
2012-10-30 |
Medimmune Limited |
Antibodies to IL-1R1
|
|
EP2385839B1
(en)
|
2009-01-09 |
2014-11-26 |
The Schepens Eye Research Institute, Inc. |
Therapeutic compositions for treatment of corneal disorders
|
|
AU2010208394A1
(en)
|
2009-01-27 |
2011-09-08 |
Hologic, Inc. |
Biomarkers for detection of neonatal sepsis in biological fluid
|
|
CN102378766A
(zh)
|
2009-03-23 |
2012-03-14 |
夸克医药公司 |
治疗癌症和纤维化疾病的化合物组合物和方法
|
|
US20120045764A1
(en)
|
2009-05-01 |
2012-02-23 |
Markus Grompe |
Method of expanding human hepatocytes in vivo
|
|
DE102009026075A1
(de)
|
2009-06-30 |
2011-01-05 |
Röhm Gmbh |
Bohrvorrichtung
|
|
WO2011017294A1
(en)
|
2009-08-07 |
2011-02-10 |
Schering Corporation |
Human anti-rankl antibodies
|
|
GB2472856B
(en)
|
2009-08-21 |
2012-07-11 |
Cantargia Ab |
IL1-RAP modulators and uses thereof
|
|
WO2011031600A1
(en)
|
2009-09-10 |
2011-03-17 |
Schering Corporation |
Use of il-33 antagonists to treat fibrotic disease
|
|
KR20120108967A
(ko)
|
2009-09-16 |
2012-10-05 |
제넨테크, 인크. |
코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
|
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
US9149544B2
(en)
|
2009-11-06 |
2015-10-06 |
The Penn State Research Foundation |
Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo
|
|
GB0919751D0
(en)
|
2009-11-11 |
2009-12-30 |
King S College Hospital Nhs Fo |
Conjugate molecule
|
|
US20130195868A1
(en)
|
2010-06-24 |
2013-08-01 |
Eleven Biotherapeutics, Inc. |
Treating surface of the eye disorders
|
|
WO2012027494A1
(en)
|
2010-08-24 |
2012-03-01 |
Regents Of The University Of Minnesota |
Bispecific targeting reagents
|
|
WO2012088290A2
(en)
|
2010-12-22 |
2012-06-28 |
Abbott Laboratories |
Tri-variable domain binding proteins and uses thereof
|
|
WO2012088302A2
(en)
|
2010-12-22 |
2012-06-28 |
Abbott Laboratories |
Half immunoglobulin binding proteins and uses thereof
|
|
RU2597831C2
(ru)
|
2011-01-19 |
2016-09-20 |
Кантаргия Аб |
Анти-il1rap антитела и их применение при лечении людей
|
|
WO2012122228A2
(en)
|
2011-03-07 |
2012-09-13 |
Temple University - Of The Commonwealth System Of Higher Education |
Biomarkers of chronic obstructive pulmonary disease
|
|
JP2014519480A
(ja)
|
2011-04-15 |
2014-08-14 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌で使用される抗ｉｌ−１ｒ１阻害物質
|
|
KR101970025B1
(ko)
*
|
2011-04-20 |
2019-04-17 |
메디뮨 엘엘씨 |
Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
|
|
CA2837651A1
(en)
|
2011-06-21 |
2012-12-27 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
|
WO2013023015A2
(en)
|
2011-08-11 |
2013-02-14 |
Albert Einstein College Of Medicine Of Yeshiva University |
Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes
|
|
US9534058B2
(en)
|
2012-02-08 |
2017-01-03 |
Abbvie Stemcentrx Llc |
Anti-CD324 monoclonal antibodies and uses thereof
|
|
US8975398B2
(en)
|
2012-05-11 |
2015-03-10 |
Abbvie Inc. |
NAMPT inhibitors
|
|
WO2014100772A1
(en)
|
2012-12-21 |
2014-06-26 |
Cellerant Therapeutics, Inc. |
Antibodies that bind membrane-bound il1rap
|
|
WO2014135655A1
(en)
|
2013-03-06 |
2014-09-12 |
Institut Curie |
Compositions and methods for treating muscle-invasive bladder cancer
|
|
JO3532B1
(ar)
|
2013-03-13 |
2020-07-05 |
Regeneron Pharma |
الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
|
|
US10118971B2
(en)
|
2013-03-13 |
2018-11-06 |
Ibentrus, Inc. |
Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor
|
|
WO2014152195A1
(en)
|
2013-03-15 |
2014-09-25 |
Regeneron Pharmaceuticals, Inc. |
Il-33 antagonists and uses thereof
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
EP4079760A3
(en)
|
2013-03-15 |
2023-01-25 |
Sanofi Pasteur Inc. |
Antibodies against clostridium difficile toxins and methods of using the same
|
|
JP2016520615A
(ja)
|
2013-05-31 |
2016-07-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法
|
|
DK3022226T3
(en)
|
2013-07-19 |
2019-03-25 |
Vib Vzw |
TARGETED MODIFIED IL-1 FAMILY MEMBERS
|
|
GB201403875D0
(en)
|
2014-03-05 |
2014-04-16 |
Cantargia Ab |
Novel antibodies and uses thereof
|
|
NO2785538T3
(https=)
|
2014-05-07 |
2018-08-04 |
|
|
|
WO2016004389A2
(en)
|
2014-07-03 |
2016-01-07 |
Abbvie Inc. |
Monovalent binding proteins
|
|
GB201413913D0
(en)
*
|
2014-08-06 |
2014-09-17 |
Cantargia Ab |
Novel antibodies and uses thereof
|
|
US10261098B2
(en)
|
2014-08-18 |
2019-04-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Biomarkers for diagnosis and management of neuro-immunological diseases
|
|
JP2016044126A
(ja)
|
2014-08-19 |
2016-04-04 |
国立大学法人埼玉大学 |
次世代型フラグメント抗体作製用ｄｎａライブラリの作製方法、その方法を用いて作製されたライブラリ、及び次世代型フラグメント抗体
|
|
CN107109494B
(zh)
|
2014-11-10 |
2023-10-27 |
豪夫迈·罗氏有限公司 |
Il-33介导型疾病的治疗方法和诊断方法
|
|
EP3218402A1
(en)
|
2014-11-10 |
2017-09-20 |
F. Hoffmann-La Roche AG |
Anti-il-1beta antibodies and methods of use
|
|
TWI705976B
(zh)
|
2014-11-10 |
2020-10-01 |
美商建南德克公司 |
抗介白素-33抗體及其用途
|
|
RS61010B1
(sr)
|
2014-11-20 |
2020-11-30 |
Hoffmann La Roche |
Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
|
|
WO2016085832A1
(en)
|
2014-11-24 |
2016-06-02 |
Albert Einstein College Of Medicine, Inc. |
Peptides for blocking il1rap protein-protein interaction and uses thereof for treatment of disease
|
|
JP6519913B2
(ja)
|
2015-02-05 |
2019-05-29 |
国立大学法人名古屋大学 |
ＩｇＥ結合性エピトープペプチドの利用
|
|
US9504694B2
(en)
|
2015-03-19 |
2016-11-29 |
Cellerant Therapeutics, Inc. |
Isoquinolidinobenzodiazepines
|
|
TW202523853A
(zh)
|
2015-03-27 |
2025-06-16 |
美商再生元醫藥公司 |
偵測生物污染物之組成物及方法
|
|
KR102261618B1
(ko)
|
2015-03-31 |
2021-06-04 |
메디뮨 리미티드 |
신규한 il33 형태, il33의 돌연변이된 형태, 항체, 검정 및 이의 이용 방법
|
|
WO2016179319A1
(en)
|
2015-05-04 |
2016-11-10 |
Cellerant Therapeutics, Inc. |
Chimeric antigen receptors with ctla4 signal transduction domains
|
|
CN107847763A
(zh)
|
2015-05-08 |
2018-03-27 |
哈佛学院院长等 |
靶向选择适合于用皮质抑素衍生物治疗的患者
|
|
JP7114460B2
(ja)
|
2015-06-26 |
2022-08-08 |
サノフィ・バイオテクノロジー |
モノクローナル抗ＩＬ－１ＲＡｃＰ抗体
|
|
HK1255234A1
(zh)
|
2015-07-16 |
2019-08-09 |
塞勒兰特治疗公司 |
经半胱氨酸取代的免疫球蛋白
|
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
TW202440904A
(zh)
|
2015-08-04 |
2024-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法（二）
|
|
EA201890891A1
(ru)
|
2015-10-06 |
2018-09-28 |
Ридженерон Фармасьютикалз, Инк. |
Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
|
|
AU2016350705A1
(en)
|
2015-11-02 |
2018-05-17 |
Janssen Pharmaceutica Nv |
Anti-IL1RAP antibodies, bispecific antigen binding molecules that bind IL1RAP and CD3, and uses thereof
|
|
CN108290955A
(zh)
|
2015-11-24 |
2018-07-17 |
塞勒兰特治疗公司 |
人源化抗-cll-1抗体
|
|
WO2017112823A1
(en)
|
2015-12-23 |
2017-06-29 |
President And Fellows Of Harvard College |
Targeted selection of patients for treatment with specific cortistatin derivatives
|
|
JP2019516362A
(ja)
|
2016-04-27 |
2019-06-20 |
ファイザー・インク |
抗ｉｌ−３３抗体、その組成物、方法および使用
|
|
EP3241845A1
(en)
|
2016-05-06 |
2017-11-08 |
MAB Discovery GmbH |
Humanized anti-il-1r3 antibodies
|
|
CN106831998B
(zh)
|
2016-06-22 |
2020-09-15 |
徐州医科大学 |
一种人il1rap特异性car及其应用
|
|
JP6848241B2
(ja)
|
2016-07-25 |
2021-03-24 |
東ソー株式会社 |
Ｆｃ結合性タンパク質を用いたＩｇＧ１の精製方法
|
|
US20190225682A1
(en)
|
2016-09-02 |
2019-07-25 |
180 Therapeutics Lp |
Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody
|
|
WO2018053552A2
(en)
|
2016-09-19 |
2018-03-22 |
Cellerant Therapeutics, Inc. |
Isoquinolidinobenzodiazepines
|
|
KR20190075084A
(ko)
|
2016-10-10 |
2019-06-28 |
셀러랜트 세라퓨틱스 인코퍼레이티드 |
이소퀴놀리디노벤조디아제핀 (iqb)-1-(클로로메틸)-2,3-디히드로-1h-벤조[e]인돌 (cbi) 이량체
|
|
US10222376B2
(en)
|
2016-11-03 |
2019-03-05 |
The Charlotte-Mecklenburg Hospital Authority |
Methods and compositions for identifying leukemic stem cells
|
|
TWI857389B
(zh)
|
2016-12-01 |
2024-10-01 |
美商再生元醫藥公司 |
治療發炎症狀的方法
|
|
WO2018112256A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
|
|
CA3046975A1
(en)
|
2016-12-15 |
2018-06-21 |
Progenity, Inc. |
Ingestible device and associated methods
|
|
PE20191548A1
(es)
|
2017-02-10 |
2019-10-24 |
Genentech Inc |
Anticuerpos contra triptasa, composiciones de estos y usos de estos
|
|
ES3052989T3
(en)
|
2017-04-13 |
2026-01-16 |
Regeneron Pharma |
Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
|
|
EP3401332A1
(en)
|
2017-05-08 |
2018-11-14 |
MAB Discovery GmbH |
Anti-il-1r3 antibodies for use in inflammatory conditions
|
|
KR102116178B1
(ko)
|
2017-05-10 |
2020-05-27 |
서울대학교산학협력단 |
간암 고위험군의 간암 발병 모니터링 또는 진단용 바이오마커 및 그 용도
|
|
US11149094B2
(en)
|
2017-06-05 |
2021-10-19 |
Janssen Biotech, Inc. |
Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
|
|
CA3066918A1
(en)
|
2017-06-12 |
2018-12-20 |
Bluefin Biomedicine, Inc. |
Anti-il1rap antibodies and antibody drug conjugates
|
|
KR102659791B1
(ko)
|
2017-07-06 |
2024-04-23 |
리제너론 파마슈티칼스 인코포레이티드 |
당단백질을 만들기 위한 세포 배양 과정
|
|
WO2019024979A1
(en)
|
2017-07-31 |
2019-02-07 |
Institute For Research In Biomedicine |
FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
|
|
KR20200038490A
(ko)
|
2017-08-01 |
2020-04-13 |
시티 오브 호프 |
항-il1rap 항체
|
|
CA3076662A1
(en)
|
2017-09-25 |
2019-03-28 |
Ecm Diagnostics, Inc. |
Methods for treating degenerative disc disease and chronic lower back pain
|
|
WO2019099993A1
(en)
|
2017-11-17 |
2019-05-23 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for alleviating cytokine release syndrome
|
|
EP3489259A1
(en)
|
2017-11-23 |
2019-05-29 |
Etablissement Français du Sang |
Anti-il-1rap-car-t cells and their use
|
|
GB201720077D0
(en)
|
2017-12-01 |
2018-01-17 |
Univ Oxford Innovation Ltd |
Leukaemic stem cell
|
|
GB201800649D0
(en)
|
2018-01-16 |
2018-02-28 |
Argenx Bvba |
CD70 Combination Therapy
|
|
AU2019218128A1
(en)
|
2018-02-09 |
2020-09-17 |
Genentech, Inc. |
Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
|
|
EP3752200A1
(en)
|
2018-02-13 |
2020-12-23 |
Vib Vzw |
Targeting minimal residual disease in cancer with rxr antagonists
|
|
GB201802307D0
(en)
|
2018-02-13 |
2018-03-28 |
Vib Vzw |
CD36 antagonists for use in melanoma treatment
|
|
US11603405B2
(en)
|
2018-05-24 |
2023-03-14 |
Janssen Biotech, Inc. |
Anti-CD3 antibodies and uses thereof
|
|
US20210155701A1
(en)
|
2018-05-30 |
2021-05-27 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide comprising il-1r1 binding domain and carrying moiety
|
|
KR20190140756A
(ko)
|
2018-06-12 |
2019-12-20 |
주식회사 노보셀바이오 |
자연 살상 세포에 결합하는 이중특이적 항체 및 이의 용도
|